Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"

(HIC# 1006007008)

TrialNet investigators want to see if an experimental medication called teplizumab may stop or slow down the autoimmune reaction that is destroying beta cells in people who are at high risk of developing type 1 diabetes. In this study, we will compare people who get infusions of teplizumab with those who get infusions that look the same but have no teplizumab, called placebo. Teplizumab is given through an intravenous (IV) infusion. The infusions are given daily for 14 days and last 30 minutes. Each visit takes about 4 hours. Follow up visits occur at various intervals.

You can be screened for this study if:
You are 8-45 years old
The tests you took in the Natural History study showed that you are at high risk for developing type 1 diabetes

For more information, contact Laurie Feldman (203) 737-2760 or laurie.feldman@yale.edu